BPG is committed to discovery and dissemination of knowledge
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Gao Z, Wang XY, Song T, Shen ZG, Wang XY, Wu SK, Jin X. Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer. World J Gastroenterol 2025; 31(29): 109947 [PMID: 40809924 DOI: 10.3748/wjg.v31.i29.109947]
Corresponding Author of This Article
Xuan Jin, PhD, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. jinxuanbdyy@outlook.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2892)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 7, 2025 (publication date) through Mar 18, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
| Gao Z, Wang XY, Song T, Shen ZG, Wang XY, Wu SK, Jin X. Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer. World J Gastroenterol 2025; 31(29): 109947 [PMID: 40809924 DOI: 10.3748/wjg.v31.i29.109947] | |
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
Cited by in CrossRef
| For: | Gao Z, Wang XY, Song T, Shen ZG, Wang XY, Wu SK, Jin X. Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer. World J Gastroenterol 2025; 31(29): 109947 [PMID: 40809924 DOI: 10.3748/wjg.v31.i29.109947] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i29/109947.htm |
| Number | Citing Articles |
Core Tip
